

This communication should be viewed by:
 Administrative Staff
 Clinical staff

Pharmacy Formulary Updates Effective September 1, 2023

The MVP Health Care® (MVP) Pharmacy and Therapeutics (P&T) Committee has determined that the following drugs, which have been recently approved by the FDA, will require prior authorization for at least the first six months following the date they are available on the market. The most current versions of our Formularies and Prior Authorization forms are available at mvphealthcare.com.

New Drugs (prior authorization required)

New Chemical Entities					
Drug Name	Indication	Commercial	Medicaid	Medicare	Exchange
Omisirge® (omidubicel)	To reduce the time to neutrophil recovery and the incidence of infection in patients aged 12 years and older with blood cancers planned for umbilical cord blood transplantation following a myeloablative conditioning regimen	Prior Authorization, Medical	Prior Authorization, Medical	Prior Authorization, Medical Part D - Excluded	Prior Authorization, Medical
Prevduo™ (neostigmine/glycopyrrolate)	The reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) after surgery, while decreasing the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) associated with cholinesterase inhibition following NMBA reversal administration, in patients aged 2 years and older	Prior Authorization, Medical	Prior Authorization, Medical	Prior Authorization, Medical Part D - Excluded	Prior Authorization, Medical
Tembexa Tablet® (brincidofovir)	The treatment of smallpox infection	Prior Authorization, Tier 3	NYRX Medicaid Transition	Nonformulary (currently Med D=N)	Prior Authorization, Tier 3
Tembexa Suspension® (brincidofovir)	The treatment of smallpox infection	Prior Authorization, Tier 3	NYRX Medicaid Transition	Nonformulary (currently Med D=N)	Prior Authorization, Tier 3

New Combinations/Formulations					
Drug Name	Indication	Commercial	Medicaid	Medicare	Exchange
Abilify Asimtufii ® (aripiprazole)	The treatment of schizophrenia, and the maintenance monotherapy treatment of bipolar I disorder in adults	Prior Authorization, Medical	Prior Authorization, Medical	Tier 5	Prior Authorization, Medical
Vowst ™ (fecal microbiota spores, live-brpk)	The prevention of recurrent Clostridium difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI	Prior Authorization per C. Difficile Drug Therapy policy, Tier 3	NYRX Medicaid Transition	Nonformulary (Prior authorization, Tier 5 when RxCUI becomes available)	Prior Authorization per C. Difficile Drug Therapy policy, Tier 3
Drug Name	Indication	Commercial	Medicaid	Medicare	Exchange
Lumryz ™ (sodium oxybate)	The treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy	Prior Authorization, Tier 3	NYRX Medicaid Transition	Nonformulary	Prior Authorization, Tier 3

New Generics for Commercial & Exchange (non-Medicare):

NEW GENERICS (all brands will be non-formulary, Tier 3)				
Brand Name	Generic Name	Commercial	Medicaid	Exchange
Iressa	Gefitinib	Tier 1	NYRX Medicaid Transition	Tier 2
Firvanq	Vancomycin solution	Tier 1	NYRX Medicaid Transition	Tier 2
Uceris	Budesonide rectal foam	Tier 1	NYRX Medicaid Transition	Tier 2

Formulary Updates

Exchange Formulary Effective January 1, 2024

Exchange 2024 Benchmark Moving Tier 2 to Tier 1
Medication
Calcitriol capsules 0.25mg
Ropinirole immediate release
Sucralfate tablet 1gm
Acamprosate Calcium Delayed Release tablet 333mg
Levalbuterol nebulizer solution
Naloxone Nasal Spray 4mg/0.1ml
Nebivolol tablet
Pramipexole tablet
Generic Suprep: Sod Sulfate-Pot Sulf- SOL 17.5-3.13-1.6 GM/177ML

It's Time to Recertify Your Patients!*

The Families First Coronavirus Response Act has expired. To learn how MVP can help your patients continue their coverage, visit mvphealthcare.com/recertification.

*Applies to Members enrolled in Medicaid, Child Health Plus (CHP), Health and Recovery Plan (HARP), and the Essential Plan (EP).

To view all communications, visit mvphealthcare.com/FastFax

Questions? Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.

